An interventional study of Go Wish Game in Leukemia, Multiple Mieloma and Advanced Solid Tumors, sponsored by Azienda USL Reggio Emilia - IRCCS. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Azienda USL Reggio Emilia - IRCCS · Not applicable, Interventional, and Health services research
This is a mixed-method, device-free and drug-free multicenter interventional study. The study aims at facilitating end-of-life conversations within the doctor-patient relationship through the use of the Go Wish Game (GWG) and supporting patients, their caregivers and healthcare professionals to complete Advance Care Panning documentation.
The GWG helps people clarify and identify their priorities, should they be affected by a chronic, disabling and potentially non-healing illness. In fact, the GWG consists of a small deck of cards, and on each card is a concrete action or situation that may be important to a person at the end of life.
The "Onco-hema Go wish-ACP" project aims to evaluate the feasibility of a Go Wish Game-based intervention with patients with refractory lymphoma, leukemia or multiple myeloma or advanced solid tumors with prognosis > 3 months.
In terms of secondary objectives, the study aims to.
2,381 studies on the registry are indexed under Leukemia; 253 are open to participants now.
This study's planned enrollment of 75 is above the median of 40 across 1,769 interventional studies indexed under Leukemia.
Browse Leukemia studies →Azienda USL Reggio Emilia - IRCCS is the lead sponsor of 93 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Go Wish Game
The Go Wish Game (GWG) provides a simple tool, composed by 35 cards to identify individual priorities. GWG is welcomed as a first step in clarifying values and personal thoughts linked to the end of life. The GWG discussion will be divided into two meetings. During the first one, the physician instructs the patients and their caregivers on how the GWG works. The patient will be invited to divide the cards into three sets, labeling the content of the cards within each set as: Very important;more or less important and not important. This will be the base for the second meeting. During the second meeting - scheduled within one week - each category of card sets will be discussed with patients and their caregivers. The identification of the most relevant wishes or priorities of each patient will be incorporated into the individual therapeutic plan and the patient will be offered the option to make a formal ACP in the following 4 weeks.
Intervention Feasibility
We will evaluate the feasibility of the intervention. Feasibility will be investigated by: 1. proportion of patients who will accept to participate among those screened/eligible who received the proposal to participate; 2. proportion of enrolled patients who will withdraw from the study after the first GWG discussion among the enrolled patients; 3, percentage proportion of enrolled patients who will attend all the planned GWG discussions; 4\. proportion of enrolled patients that will complete the ACP document (after participating in all the planned GWG discussions)
Time frame: 1 Year
ACP Engagement;
We will further assess and compare the intervention within hemato-oncological and oncological patients in terms of: 1\. ACP engagement: we will use the 4-item ACP Engagement (4-item ACP-E) questionnaire
Time frame: 18 Months
Quality of Communication;
We will further assess and compare the intervention within hemato-oncological and oncological patients in terms of: 2\. Quality of communication: we will use the 19-item Quality of Communication (QOC) questionnaire
Time frame: 18 Months
Meaning of Life;
We will further assess and compare the intervention within hemato-oncological and oncological patients in terms of: 3\. Meaning of life: we will use the Meaning in Life scale (MLS)
Time frame: 18 Months
Impact on patients' hope
We will further assess and compare the intervention within hemato-oncological and oncological patients in terms of: 4\. Impact on patients' hope: we will use the Hope Herth Index (HHI)
Time frame: 18 Months
Acceptability
5\. Acceptability of intervention in terms of recruitment and intervention delivery will be further investigated by: semi-structured interviews with patients and caregivers and FG with HPs who applied the GWG. .
Time frame: 18 Months
ACP documentation
We will analyze the ACP documentation of patients enrolled to qualitatively investigate the congruence and relations between the priorities defined during the GWG meetings and the decisions written in the care plan
Time frame: 18 Months
Plan to share: Yes — We share individual information about gender, age, work occupation, disease type, prognosis and time of diagnosis.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Access criteria: The access will be able only to those people in terms of clinical staff, who are involved in the study
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda USL Reggio Emilia - IRCCS